• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186924 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  2 B; d- D8 [6 T2 F# _- A
  U. r! o2 V0 ^. X$ O

/ {$ j3 m' E! [: xSub-category:6 y& t, B: I6 j) D% R4 _; A
Molecular Targets 3 d7 j+ C1 Q4 z; C  {, b
% X% N2 O: }3 K( j: d
, r8 `: R5 J* w8 }# r( V! V
Category:8 W! r1 n: R- c9 k: ^% E0 ]$ o
Tumor Biology : X' P$ f: [% k5 A

7 j; K8 W: h. K4 M! K8 f( M. c1 k# p* s1 Q/ o
Meeting:
0 p" \& w/ o0 u0 d, a! d2011 ASCO Annual Meeting
* V2 Y' L4 V0 z: S0 j9 k# K3 u9 O: [2 v, w7 L& X2 v+ C' P+ Q

- C- h6 R# Q. l/ M* _1 |  L3 g6 ]; |Session Type and Session Title:( g6 Y# G# E+ U. F" }
Poster Discussion Session, Tumor Biology ; [1 p6 m4 z' [( d9 F7 e* X6 i

. o6 G9 L8 h  P
+ N: g: @; U/ e2 m4 H( X* `Abstract No:
3 ]7 |8 V5 W' p% l10517
4 {( ^5 d- B: H/ g' a; |( }7 x) Z5 ~$ U2 `9 |( R2 `: d# G
" j1 i, T2 x! [7 F& w
Citation:
/ {; @- W" o" tJ Clin Oncol 29: 2011 (suppl; abstr 10517)
% C) w8 D3 S( D# C1 ^4 L
5 E' C* A7 M9 T# G8 O* R/ T' O! P  e; K" m. ?# I. U
Author(s):
) y$ s5 V7 `, U8 Q, [  E) LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 1 r0 i  P% G9 B( u0 u4 {: ~

) I3 `$ `7 v% ]2 K- N+ J" L2 }! E/ Y

. B7 o; v2 F0 V+ t) \Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* y7 H$ D* x% ]! S: W, y( M6 \0 d2 v& M, s# W5 i: t
Abstract Disclosures; M7 D1 X$ Y+ T- I1 s
- H( M: D0 O, b* U3 V1 O
Abstract:
& T9 y* }- \5 c9 x1 c( c; N5 _1 @, h
5 B" n( m; I! Q$ ~
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
" }' [$ T. E; W$ v8 S0 }
9 [! S) h. ^1 J' X% N5 i
% z7 V/ U+ Y, f& Y, e! C+ a
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
) h, s  |. D* {& v, j没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

% I! |  g0 i/ f% {6 [, `化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
/ {3 |5 v6 G7 {+ z$ u: @易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
! i; Q/ ~) ^; @4 d" IALK一个指标医院要900多 ...
  J3 Z# R3 b) h7 L$ R* `* c% O: l
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
* ^: N6 j# T# ~( B" `9 M/ \; l& \- O* f, l) v" W8 y$ S
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表